It has been established that the binding of the Spike S Protein of the SARS-CoV-2 virus to the host cell’s ACE2 receptor triggers a series of molecular events. This results in the entry of the virus into the host cell. The viral entry activates an immune response in the host to resolve the resulting infection. Depending on the magnitude and duration of the viral load and the time taken by the body to activate the immune response, the SARS-CoV-2 infection may result in asymptomatic / mild / moderate / severe COVID-19 disease. In critically ill patients it may even cause death.

COROQUIL-Zn is designed to counter the binding of the Spike S Protein of the SARS-CoV-2 virus to the ACE2 receptor. Thus the  entry of the virus to the host cell is blocked. The formulation of COROQUIL-Zn is the result of developing a series of cell-based experiments to study the activity of plant extracts. We have also conducted pilot experiments on hamsters. All the pre-clinical laboratory experiments were carried out in collaboration with the University of Missouri, USA.